Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
X
Share Page
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts

2013 Press Releases

Webcast ImageWebcast
vTv Therapeutics Inc. at Needham & Co. 16th Annual Healthcare Conference (Live)
04/04/17 at 4:20 p.m. ET
vTv Therapeutics Inc. at Needham & Co. 16th Annual Healthcare Conference
Tuesday, April 4, 2017 4:20 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
08/14/13First Liver-Selective Glucokinase Activator for Type 2 Diabetes Demonstrates Normalized HbA1c and No Hypoglycemia in Clinical Trial
High Point, North Carolina (August 14, 2013)TransTech Pharma Inc. announced today important clinical trial data for its new diabetes drug. TTP399, a novel, liver-selective glucokinase activator (GKA), demonstrated clinical evidence of normalizing HbA1c without inducing hypoglycemia in type 2 diabetic subjects on stable doses of metformin. TTP399 is the first liver-selective GKA that shows no GKA activation in the pancreas and does not interrupt the binding of glucokinase (GK) with the GK regulat... 
Printer Friendly Version
07/01/13TransTech Pharma Completes End of Phase 2 Meeting with FDA for TTP488
High Point, North Carolina (July 1, 2013)TransTech Pharma Inc. announced today that it has successfully completed an End of Phase 2 meeting for TTP488 with the U.S. Food and Drug Administration (FDA). TTP488 is under development for the treatment of mild to moderate Alzheimer’s disease. The FDA Division of Neurology Products agreed that the data from the completed Phase 2 clinical trial is sufficient to support the start of a Phase 3 registration program. The FDA concurred with TransTech’s propo... 
Printer Friendly Version
03/18/13FDA Grants TransTech Pharma Inc. Fast Track Designation for TTP488 for the Treatment of Alzheimer's Disease
High Point, North Carolina (March 18, 2013)TransTech Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for TTP488, a new small-molecule chemical compound being developed for the treatment of Alzheimer’s disease. TTP488 prevents the interaction of amyloid beta (Ab), a material found in the cells of Alzheimer’s patients, and a member of the immunoglobulinsupergene family of moleculesknown as the Receptor for Advanced GlycationEndproduct... 
Printer Friendly Version